BACKGROUND: Current approaches to measure protein turnover that use stable isotope-labeled tracers via GC-MS are limited to a small number of relatively abundant proteins. We developed a multiplexed liquid chromatography-selected reaction monitoring mass spectrometry (LC-SRM) assay to measure protein turnover and compared the fractional synthetic rates (FSRs) for 2 proteins, VLDL apolipoprotein B100 (VLDL apoB100) and HDL apoA-I, measured by both methods. We applied this technique to other proteins for which kinetics are not readily measured with GC-MS.
labeled with stable isotopes. LC-SRM is amenable to a multiplexed format to provide a relatively rapid and inexpensive means to measure turnover of multiple proteins simultaneously.
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Kinetic measurements of plasma proteins are useful for studying metabolic changes in patients under a variety of physiological conditions. These dynamic measurements can supplement protein concentration measurements and provide information about synthesis and turnover rates. Protein kinetics studies have been used to determine the mechanisms responsible for changes in protein concentration in studies involving nutritional (1 ) and drug interventions (2, 3 ) , as well as to study metabolic abnormalities in patients with genetic mutations (4 ) .
The gold standard for protein kinetic measurements is exogenous labeling of purified protein, typically with radiotracers, followed by reinjection of labeled protein into plasma. The clearance rate of protein is measured by following the decrease in labeled protein from plasma over time (5 ) . However, this method is frequently impractical owing to difficulties in obtaining sufficient quantities of purified protein for labeling and the risks associated with exposure to radioactivity. For this reason, many laboratories use protocols that endogenously label proteins with stable isotope-labeled amino acid tracers. After tracer administration, proteins of interest are isolated from plasma, hydrolyzed to their constituent amino acids, and derivatized, and the stable isotope enrichment of the tracer amino acid in the protein is measured at each time point with GC-MS. The change in stable isotope enrichment in the protein over time is analyzed to determine production and clearance rates (1 ) .
Whereas this technique provides results that are comparable to those obtained with radioactive tracers (5 ) , it has a number of limitations. It can be done only on a highly purified protein and requires multiple analyses if more than 1 protein is to be studied. In addition, because this technique measures amino acid enrichment with stable isotope following protein hydrolysis, it is sensitive to contamination from protein and amino acids in water and other reagents during processing (6 ) . Moreover, the protein must be of sufficient abundance, typically Ͼ1 g, for reliable detection.
In 2006, Bateman et al. (7 ) reported a novel LC-MS-based method to measure the endogenous labeling of amyloid-␤ in cerebrospinal fluid with a stable isotope-labeled amino acid tracer. Unlike the GC-MSbased method, which measures amino acid enrichment of a purified protein with stable isotope after protein hydrolysis, this new method measured stable isotope enrichment of tryptic peptides of a purified protein with LC-MS (7 ). We applied a modification of this LC-MS-based method to the study of proteins associated with lipoprotein metabolism. We determined the fractional synthetic rate (FSR) 6 of 2 proteins, VLDLapolipoprotein B100 (VLDL apoB100) and HDLapoA-I, by use of the classic GC-MS approach that measures amino acid enrichment of the hydrolysate of the protein of interest. We then compared this FSR to that obtained with tracer enrichment data of the same proteins measured in tryptic peptide fragments by triple quadrupole mass spectrometry. Finally, we applied this technique to other proteins involved in lipoprotein metabolism for which kinetics are not readily measured with the established GC-MS-based approach.
Materials and Methods

SUBJECTS, EXPERIMENTAL PROTOCOL, AND GC-MS TRACER ENRICHMENT MEASUREMENTS
All protocols and procedures were approved by the Human Investigational Review Board at the University of Pennsylvania. All subjects gave written informed consent.
We measured apolipoprotein kinetics under constantly-fed conditions as described (3 ) and as described in Supplemental Methods, which accompanies the online version of this article at http://www. clinchem.org/content/vol58/issue3. We isolated lipoprotein fractions by sequential ultracentrifugation as described in online Supplemental Methods.
VLDL apoB100 was isolated from the triglyceride-rich lipoprotein (TRL) fraction and apoA-I was isolated from the HDL fraction (density 1.063-1.21 g/mL) with SDS-PAGE, followed by staining with Coomassie Blue R250 and analysis of the free amino acids by GC-MS as described (8 ) and as described in online Supplemental Methods. We determined the tracer enrichment ratio by regression analysis of the instrument-measured isotopomer ratio against standards of known enrichment ratios (4 ). The detection limit for tracer enrichment determination was 0.09%, CV 6.7%.
BIOCHEMICAL SAMPLE PROCESSING FOR LC-MS MEASUREMENTS
Plasma samples from each subject at all time points were thawed at 4°C. A 20-L aliquot was diluted to 300 L with 50 mmol/L ammonium bicarbonate (pH 8), reduced with 10 mmol/L dithiothreitol (DTT) at 60°C for 45 min, alkylated with 10 mmol/L iodoacetamide at room temperature for 30 min in the dark, reduced again with 5 mmol/L DTT at room temperature for 30 min in the dark, and digested overnight at 37°C with modified trypsin at a 1:50 (wt/wt) trypsin:total protein ratio. Digested plasma samples were quenched with 20 L glacial acetic acid and desalted with Sep-Pak C18 cartridges. Desalted samples were lyophilized to dryness and reconstituted in 200 L of 0.1% formic acid in water before mass spectrometric analysis.
We immunoprecipitated human plasma, 0.5 mL for cholesteryl ester transfer protein (CETP) and 1.5 mL for proprotein convertase subtilisin/kexin type 9 (PCSK9), with an anti-CETP monoclonal antibody (TP2) or an anti-PCSK9 monoclonal antibody (1B20) immobilized to Tosylactivated Dynabeads. Immunoprecipitated proteins were eluted from beads with SDS-PAGE sample buffer and separated by SDS-PAGE. Proteins were visualized by staining with SimplyBlue Safestain (Invitrogen). Stained gels were stored at 4°C in 5% acetic acid until ready for analysis.
We prepared TRL fractions by ultracentrifugation (described above). For each subject sample, we added 32 L of the TRL fractionated material to 5ϫ sample buffer (Pierce) containing 1:20 (vol/vol) ␤-mercaptoethanol and 100 nmol/L N-ethylmaleimide. Samples were run on 10%-20% Criterion Gels (Bio-Rad) at 200 V for 1 h. Gel bands containing apoB100, apoE, and comigrating apoC-I, apoC-II, and apoC-III were excised with an EXQuest Spot Cutter (Bio-Rad). Protein gel bands were excised into 96-well plates and processed with an automated in-gel digestion protocol developed on a Tecan Freedom EVO automated liquid handler with EVOware standard software, as described in online Supplemental Methods.
We analyzed recovered mixtures of native and metabolically labeled tryptic peptides by liquid chromatography-tandem mass spectrometry (LC-MS/ MS). Method details are provided in online Supplemental Methods.
KINETIC ANALYSIS
We measured protein turnover using the FSR, a measure of the fraction of the circulating protein pool synthesized per unit time. We measured FSRs for all proteins by use of the WinSAAM modeling program by fitting a rising monoexponential curve containing a 30-min secretory delay to the tracer data (5 ). All proteins were assumed to have the same precursor enrichment, which was estimated from the corresponding VLDL apoB100 tracer data. The equation used to determine the FSR and precursor enrichment from the tracer data was
where E(t) is tracer enrichment at time t, A is estimate of VLDL apoB100 precursor enrichment, r is FSR, and d is the assumed secretory delay of 0.5 h.
Results
SELECTION OF PEPTIDES AND PRECURSOR AND PRODUCT IONS
To identify tryptic peptides for use in an apoB100 or apoA-I mass spectrometry assay, we used Skyline, a free open-source software tool (9 ) , to search the human protein database for peptide sequences unique to apoB100 or apoA-I and not present in other human proteins. Because the goal was to develop an assay to measure the incorporation of stable isotope-labeled [5,5,5-D 3 ]-leucine (D 3 -leucine), we required the presence of 1 or more leucine residues and absence of methionine or cysteine residues. Using this information as well as previously published data (10, 11 ), we selected 1 peptide from apoB100, FPEVDVLTK, and 1 peptide from apoA-I, DYVSQFEGSALGK, for further development (see online Supplemental Table 1 ).
The analytical sensitivity and selectivity of LC-MS/MS is derived, in part, by selective reaction monitoring (SRM), which is the detection of ions that undergo a gas-phase dissociation reaction from a specific precursor m/z to a specific product m/z. Fig. 1 , A and B, show the isotope distribution for the (Mϩ2H) 2ϩ precursor ion for the naturally occurring peptide DYVSQFEGSALGK and the D 3 -leucine-labeled peptide, respectively. At a Q1 peak width setting of 0.2 FWHM (full width at half maximum), the unlabeled peptide at m/z 700.8 was 
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readily distinguished from the heavy labeled peptide at m/z 702.3; even at this narrow peak width setting, however, the heavy labeled peptide at m/z 702.3 overlapped with the naturally occurring Mϩ3 isotope of the light peptide at m/z 702.3 (Fig. 1, A and B) . This fact is important to the selection of the product mass. To determine the most abundant transitions, we analyzed synthetic peptides. Fig. 1, C and D, show the product spectra for the unlabeled and labeled peptide, respectively. To select the transitions in the assay, because the doubly charged precursor mass is the most abundant for this peptide, we looked to measure a singly charged product ion that contained the leucine residue and was larger in mass than the precursor ion. On the basis of these criteria, the y 10 ϩ product ion was chosen. The y 10 product ions for the heavy and light peptides were readily distinguished in the product spectra (Fig. 1, C and D).
METHOD EVALUATION
We developed our LC-SRM assay to measure a 1% stable isotope incorporation. To show it was possible to measure trace concentrations of a labeled peptide in a large excess (100-fold) of the unlabeled peptide, we mixed light and heavy synthetic peptides at a 100:1 ratio and added this mixture to a complex background (Fig. 2, A and B) . First, we used serial dilution to prepare standards at successively lower concentrations. We anticipated that the ability to measure 1% incorporation accurately would diminish as the y 10 ϩ signal intensity decreased. The mass spectrometer signal response was linear over a range of 5 orders of magnitude ( Fig. 2A) . Next, we examined the measured ratio of the heavy and light peptides as a function of y 10 ϩ signal response for each of these dilutions. Fig. 2B shows the measured ratio (Mϩ3/Mϩ0) as a function of Mϩ0 signal response. When the Mϩ0 signal was large, both the Mϩ0 and Mϩ3 isotopomer signals were measurable, resulting in a ratio of 0.01 that could be measured accurately (Fig. 2B) . As anticipated, as the Mϩ0 signal decreased, our ability to measure the minor Mϩ3 component was diminished and the ratio deviated from 0.01. This deviation in the ratio measurement was found to occur when the Mϩ0 signal dropped below 4 ϫ 10 6 and established the minimum signal needed to accurately measured 1% incorporation of the isotopically labeled peptide. This approach was repeated to establish cutoff values for the peptides studied (peptides from apoB100, apoE, apoC-II, apoC-III, CETP, and PCSK9), which are listed in online Supplemental Table 1 .
To compare the LC-SRM method with the established GC-MS method, we measured D 3 -leucine incorporation into HDL apoA-I and VLDL apoB100 on identical samples using both methods. Fig. 3, A and B, show the 2-way plot of % D 3 -leucine incorporation by the classic GC-MS method compared with the % labeled-to-unlabeled measurement made by LC-SRM for HDL apoA-I and VLDL apoB100, respectively. The correlation between measurements made with the 2 methods showed an R 2 value Ͼ0.9 for each protein as determined by a linear regression analysis.
To calculate the FSR from stable isotope enrichment values, we performed curve fitting of the tracer incorporation data from each subject on an individual basis (Fig. 4) . The HDL apoA-I FSR measured by classic GC-MS was 0.25 pools per day, which compared favorably to the mean apoA-I FSR of 0.26 measured on apoA-I isolated from HDL and 0.27 on apoA-I isolated from plasma with the peptide approach ( Table 1) . Similarly, the mean VLDL apoB100 FSR measured by clas- sic GC-MS was 4.47 pools per day, which compared favorably to the mean apoA-I FSR of 6.76 measured on apoB100 isolated from VLDL. The VLDL apoB100 FSR measured with the peptide approach was slightly higher than that measured with the classic approach although the relative differences measured between subjects were the same for both methods.
EXTENSION OF METHOD TO OTHER PROTEIN ANALYTES
To apply this method to other proteins involved in lipoprotein metabolism, we measured D 3 -leucine incorporation into the apoE, apoC-II, apoC-III, CETP, and PCSK9 peptides (see Supplemental Table 1 ) by LC-SRM using the cutoff values described earlier. First, we targeted other proteins of interest in lipoprotein fractions to determine if the turnover of multiple proteins related to lipoprotein metabolism could be measured. The bands for apoE (molecular weight approximately 34 kDa) and the apoCs (containing a mixture of apoC-I, C-II, and C-III, which all have a molecular weight of approximately 8 kDa) were excised from the SDS-PAGE gel run on the TRL fraction. Bands were digested, and the peptides unique to each protein were analyzed with the LC-SRM method to measure D 3 -leucine incorporation. With this method, there was not sufficient signal obtained for the apoC-I peptide to obtain reliable enrichment measurements; however, sufficient tracer was measured for apoE, C-II, and C-III. The tracer enrichment curves for these proteins are shown in Fig. 4 . The FSRs calculated for apoE, apoC-II, and apoC-III by use of the tracer enrichment data compare favorably with those reported in the literature ( Table 2) .
We also attempted to measure the FSRs of 2 additional plasma proteins that are known to regulate lipoprotein metabolism, CETP (3, 12 ) and PCSK9 (13, 14 ) . These proteins were immunoprecipitated from plasma and further purified by SDS-PAGE, and then the protein digests were analyzed with LC-SRM. In both instances there was sufficient protein to provide reliable measurements for 3 of the 4 subjects studied. For CETP, the labeled and unlabeled peptides could not be fully resolved on the basis of m/z. As a result, background subtraction was performed to remove the contribution (approximately 6.5%) of the unlabeled peptide to SRM transition for the labeled peptide. The tracer incorporation curves for CETP and PCSK9 are included as online Supplemental Figs. 1 and 2 . The FSRs calculated for CETP and PCSK9 (Table 2) ranged from 0.38 to 0.53 pools/day for CETP and from 1.44 to 4.25 pools/day for PCSK9.
Discussion
Over the past several years, rapid advances in proteomic analysis have allowed for the quantitative measurement of hundreds of proteins in cell lysates, tissue, and even intact proteins (15) (16) (17) . Although proteomic measurements are useful for characterizing phenotypes, they are static measurements and do not provide any insights into the dynamic properties of proteins. In vivo protein kinetic measurements allow for the determination of changes in production and turnover rates under a variety of conditions. For example, comparisons can be made among groups with differing genetic variation as well as among groups participating in lifestyle and drug interventions.
We developed a peptide technique involving the use of a triple quadrupole mass spectrometer that allows kinetic measurement of proteins with relatively low abundance in plasma. It has the added advantages over current GC-MS-based methods that measure stable isotope enrichment in protein hydrolysates of not being susceptible to contamination from exogenous amino acids in reagents, and it can be used to measure the kinetics of multiple proteins in a single sample.
The LC-SRM method compared favorably with the classic GC-MS approach conducted on purified protein, with the enrichment measurements being highly correlated. The resulting HDL apoA-I and VLDL apoB100 FSRs calculated from data measured by use of both methods also compared favorably. Importantly, data obtained by use of the LC-SRM method allows measurement of kinetics for proteins with rapid and slow turnover rates and will be a useful approach to accurately and reliably measure protein kinetics. We found that the FSRs for apoE, C-II, and C-III measured in the current study are similar to values reported in the literature. Because the LC-SRM method is not subject to the effects of exogenous amino acid contamination or interference from comigrating proteins, it should, in theory, provide more accurate measure of tracer enrichment than the classic GC-MS approach. This may, in part, explain the minor differences in FSR measurements observed between the 2 methods. This could also be due to differences in the standards used to measure D 3 -leucine enrichment, since different sets of standards were used for each analysis. This is an important point that requires further investigation.
We also measured the FSRs for CETP and PCSK9, 2 proteins for which the kinetics have not been previously reported in humans. CETP, a protein that is known to interact with HDL and VLDL, has a relatively slow FSR of about 0.40 pools/day, slightly more rapid than that measured for HDL apoA-I (approximately 0.26 pools/day). The relatively slow FSR measured is consistent with the findings that CETP is largely associated with HDL in plasma (18 ) and that the concentrations remain relatively constant over the course of the day (19 ) . In contrast, PCSK9 had a more rapid FSR of about 2-4 pools/day, which was slightly less than that for VLDL apoB100 (approximately 6.5 pools/day). A relatively rapid FSR would be expected for a diurnal protein with a concentration that rapidly changes over a 6-h period (20 ) . The FSR for these proteins were calculated under the assumption that the precursor D 3 -leucine amino acid enrichment was the same as that estimated for VLDL apoB100. This assumption may not be valid for proteins made outside of the liversuch as CETP, which is made in both liver and adipose tissue-in which case the FSR may be different from that measured in the present study. It would be worthwhile to test the validity of the assumption by either direct or indirect measurement of the precursor D 3 -leucine enrichment for proteins made in tissues other than liver.
For the proteins measured in the LC-SRM method, the abundance ranged from approximately 130 mg/dL for the most abundant protein, apoA-I, to approximately 30 g/dL for the least abundant protein measured in this study, PCSK9. Because apoA-I abundance is so high, the LC-SRM assay has sufficient sensitivity to measure apoA-I from neat plasma. The other, less abundant, analytes require a biochemical enrichment step before analysis, either by ultracentrifugation (apoE, apoCII, and apoCIII) or immunoenrichment (CETP and PCSK9). The LC-SRM % D 3 -leucine label incorporation measurements of apo C-I did not meet the specified thresholds as defined in "Materials and methods," suggesting that biochemical enrichment is needed for apo-C1 (as was performed for PCSK-9) or a larger starting volume of plasma. For both assays, the cost per analysis is comparable, with most of the cost due to labor to run the assay. The current cost estimate is approximately $50/sample (depending on labor cost). For each LC-SRM assay, the end-to-end cycle time is approximately 1 week to analyze a batch of samples (i.e., a 96-well plate). For the LC-SRM analysis, the run time is approximately 15 min for each sample. The LC-SRM assay is currently configured with 1 LC-MS instrument and is scalable to run hundreds of samples per week. A distinct advantage of the LC-SRM assay, however, is the potential to provide multiplexed analysis in the same assay. For example, another band corresponding to another protein would result in only slight or marginal increases in cost per sample without any increase in run time. This provides substantial savings in cost and time over GC-MS, which requires separate sample preparation and analysis for each protein studied.
Our strategy in developing this LC-SRM method was first to directly compare the tracer enrichment results generated on the same proteins, VLDL apoB100 and HDL apoA-I, by use of the established GC-MS method and the LC-SRM approach. In addition, we performed protein based pull-down of CETP and PCSK9 in plasma in these studies using antibodies specific for each protein. On the basis of the experience gained in these experiments, we anticipate that future directions toward developing a simplified, inexpensive, and highly multiplexed protein turnover measurement may involve elimination of the gel-based isolation step altogether and include the use of a SISCAPA (stable isotope standards and capture by antipeptide antibodies) assay (21 ) . SISCAPA is based on the enzymatic digestion of serum or plasma and enrichment of unique peptide sequences based on peptide-specific antibodies. In general, we estimate that it would take about half the time (3.5 days rather than a week) to run the SISCAPA assay compared with the current LC-SRM assay and require about half the labor. The reduction in labor is achieved as the gel-based step is completely eliminated from the workflow and the entire procedure is readily automatable in a 96-well or larger format (22 ) . In addition, the amount of antipeptide antibody required can be optimized to enrich for low-and high-abundance proteins simultaneously. The trade-off for this approach is that a custom antipeptide antibody specific for the target protein needs to be generated. The ability for multiplexed LC-SRM assay to perform stable isotope-label enrichment measurements for 10 -50 proteins in a single run makes these type of assays highly attractive in settings where multiple protein kinetic measurements are desired. This approach would also have the advantage of allowing protein concentration measurements to be made in the same analysis, which could then be used in the calculation of absolute synthesis rates of multiple proteins. Indeed, simultaneous quantification of apoA-I and apoB from human plasma by LC-SRM has recently been demonstrated (11 ).
In conclusion, we describe an LC-SRM-based method to simultaneously measure the FSRs of multiple proteins. The method is similar in cost and turnaround to the classic GC-MS-based approach but has the potential to be applied to a wider number of proteins. This method should prove useful in providing a dynamic measure of protein metabolism and insights into the mechanism responsible for changes in protein concentration. 
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